1
|
Collantes M, Vairo C, Erhard Á, Navas C, Villullas S, Ecay M, Pareja F, Quincoces G, Gainza G, Peñuelas I. Preclinical safety of negatively charged microspheres (NCMs): optimization of radiolabeling for in vivo and ex vivo biodistribution studies after topical administration on full-thickness wounds in a rat model. Eur J Pharm Biopharm 2022; 177:61-67. [PMID: 35697288 DOI: 10.1016/j.ejpb.2022.06.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2021] [Revised: 06/01/2022] [Accepted: 06/04/2022] [Indexed: 11/15/2022]
Abstract
Negatively charged microspheres (NCMs) are postulated as a new form of treatment for chronic wounds. Despite the efficacy shown at clinical level, more studies are required to demonstrate their safety and local effect. The objective of the work was to confirm the lack of NCM systemic absorption performing a biodistribution study of the NCMs in an open wound rat animal model. To this end, radiolabeling of NCMs with technetium-99m was optimized and biodistribution studies were performed by in vivo SPEC/CT imaging and ex vivo counting during 24 h after topical administration. The studies were performed on animals treated with a single or repeated dose to study the effect of macrophages during a prolonged treatment. NCM radiolabeling was achieved in a simple, efficient and stable manner with high yield. SPECT/CT images showed that almost all NCMs (about 85 %) remained on the wound for 24 h either after single or multiple administrations. Ex vivo biodistribution studies confirmed that there was no accumulation of NCMs in any organ or tissue except in the wound area, suggesting a lack of absorption. In conclusion, NCMs can be considered safe as local wound treatment since they remain at the administration area.
Collapse
Affiliation(s)
- María Collantes
- Translational Molecular Imaging Unit (UNIMTRA), Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; RADIOMIN Research Group, Radiopharmacy Unit, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; Nuclear Medicine Department, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Spain
| | - Claudia Vairo
- BioKeralty Research Institute AIE, Albert Einstein, 25-E3, 01510, Miñano, Spain
| | - Álvaro Erhard
- Translational Molecular Imaging Unit (UNIMTRA), Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; RADIOMIN Research Group, Radiopharmacy Unit, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; Nuclear Medicine Department, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain
| | - Cristina Navas
- Translational Molecular Imaging Unit (UNIMTRA), Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain
| | - Silvia Villullas
- BioKeralty Research Institute AIE, Albert Einstein, 25-E3, 01510, Miñano, Spain
| | - Margarita Ecay
- Translational Molecular Imaging Unit (UNIMTRA), Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; RADIOMIN Research Group, Radiopharmacy Unit, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; Nuclear Medicine Department, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain
| | - Félix Pareja
- Nuclear Medicine Department, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain
| | - Gemma Quincoces
- RADIOMIN Research Group, Radiopharmacy Unit, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; Nuclear Medicine Department, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Spain
| | - Garazi Gainza
- BioKeralty Research Institute AIE, Albert Einstein, 25-E3, 01510, Miñano, Spain.
| | - Iván Peñuelas
- Translational Molecular Imaging Unit (UNIMTRA), Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; RADIOMIN Research Group, Radiopharmacy Unit, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; Nuclear Medicine Department, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Spain
| |
Collapse
|
2
|
Chang LH, Chuang EY, Cheng TM, Lin C, Shih CM, Wu AT, Jheng PR, Lu HY, Shih CC, Mi FL. Thrombus-specific theranostic nanocomposite for codelivery of thrombolytic drug, algae-derived anticoagulant and NIR fluorescent contrast agent. Acta Biomater 2021; 134:686-701. [PMID: 34358695 DOI: 10.1016/j.actbio.2021.07.072] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2021] [Revised: 07/13/2021] [Accepted: 07/29/2021] [Indexed: 12/12/2022]
Abstract
Thrombolysis is a standard treatment for rapidly restoring blood flow. However, the application of urokinase-type plasminogen activator (Uk) in clinical therapy is limited due to its nonspecific distribution and inadequate therapeutic accumulation. Precise thrombus imaging and site-specific drug delivery can enhance the diagnostic and therapeutic efficacy for thrombosis. Accordingly, we developed a P-selectin-specific, photothermal theranostic nanocomposite for thrombus-targeted codelivery of Uk and indocyanine green (ICG, a contrast agent for near-infrared (NIR) fluorescence imaging). We evaluated its capabilities for thrombus imaging and enzyme/hyperthermia combined thrombolytic therapy. Mesoporous silica-coated gold nanorods (Si-AuNRs) were functionalized with an arginine-rich peptide to create an organic template for the adsorption of ICG and fucoidan (Fu), an algae-derived anticoagulant. Uk was loaded into the SiO2 pores of the Si-AuNRs through the formation of a Fu-Uk-ICG complex on the peptide-functionalized template. The Fu-Uk/ICG@SiAu NRs nanocomposite increased the photostability of ICG and improved its targeting/accumulation at blood clot sites with a strong NIR fluorescence intensity for precise thrombus imaging. Furthermore, ICG incorporated into the nanocomposite enhanced the photothermal effect of Si-AuNRs. Fu, as a P-selectin-targeting ligand, enabled the nanocomposite to target a thrombus site where platelets were activated. The nanocomposite enabled a faster release of Uk for rapid clearing of blood clots and a slower release of Fu for longer lasting prevention of thrombosis regeneration. The nanocomposite with multiple functions, including thrombus-targeting drug delivery, photothermal thrombolysis, and NIR fluorescence imaging, is thus an advanced theranostic platform for thrombolytic therapy with reduced hemorrhaging risk and enhanced imaging/thrombolysis efficiency. STATEMENT OF SIGNIFICANCE: Herein, for the first time, a P-selectin specific, photothermal theranostic nanocomposite for thrombus-targeted co-delivery of urokinase and NIR fluorescence contrast agent indocyanine green (ICG) was developed. We evaluated the potential of this theranostic nanocomposite for thrombus imaging and enzyme/hyperthermia combined thrombolytic therapy. The nanocomposite showed multiple functions including thrombus targeting and imaging, and photothermal thrombolysis. Besides, it allowed faster release of the thrombolytic urokinase for rapidly clearing blood clots and slower release of a brown algae-derived anticoagulant fucoidan (also acting as a P-selectin ligand) for prevention of thrombosis regeneration. The nanocomposite is thus a new and advanced theranostic platform for targeted thrombolytic therapy.
Collapse
Affiliation(s)
- Lee-Hsin Chang
- School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan; Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan
| | - Er-Yuan Chuang
- Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan
| | - Tsai-Mu Cheng
- The PhD Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan; Taipei Heart Institute, Taipei Medical University, Taipei 11031, Taiwan
| | - Chi Lin
- Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan
| | - Chun-Ming Shih
- Taipei Heart Institute, Taipei Medical University, Taipei 11031, Taiwan; Division of Cardiology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 11031, Taiwan; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan
| | - Alexander Th Wu
- The PhD Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan; Taipei Heart Institute, Taipei Medical University, Taipei 11031, Taiwan
| | - Pei-Ru Jheng
- Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan
| | - Hsin-Ying Lu
- Taipei Heart Institute, Taipei Medical University, Taipei 11031, Taiwan; Division of Cardiovascular Surgery, Department of Surgery, Wan Fang Hospital, Taipei Medical University, Taipei 11031, Taiwan; Institute of Clinical Medicine, School of Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan
| | - Chun-Che Shih
- Taipei Heart Institute, Taipei Medical University, Taipei 11031, Taiwan; Division of Cardiovascular Surgery, Department of Surgery, Wan Fang Hospital, Taipei Medical University, Taipei 11031, Taiwan; Institute of Clinical Medicine, School of Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan; Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
| | - Fwu-Long Mi
- Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan; Taipei Heart Institute, Taipei Medical University, Taipei 11031, Taiwan; Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan; Graduate Institute of Nanomedicine and Medical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.
| |
Collapse
|
3
|
Raychaudhuri R, Naik S, Shreya AB, Kandpal N, Pandey A, Kalthur G, Mutalik S. Pullulan based stimuli responsive and sub cellular targeted nanoplatforms for biomedical application: Synthesis, nanoformulations and toxicological perspective. Int J Biol Macromol 2020; 161:1189-1205. [PMID: 32504712 DOI: 10.1016/j.ijbiomac.2020.05.262] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Revised: 05/23/2020] [Accepted: 05/29/2020] [Indexed: 01/27/2023]
Abstract
With growing interest in polymers of natural origin, innumerable polysaccharides have gained attention for their biomedical application. Pullulan, one of the FDA approved nutraceuticals, possesses multiple unique properties which make them highly advantageous for biomedical applications. This present review encompasses the sources, production, properties and applications of pullulan. It highlights various pullulan based stimuli-responsive systems (temperature, pH, ultrasound, magnetic), subcellular targeted systems (mitochondria, Golgi apparatus/endoplasmic reticulum, lysosome, endosome), lipid-vesicular systems (solid-lipid nanoparticles, liposomes), polymeric nanofibres, micelles, inorganic (SPIONs, gold and silver nanoparticles), carbon-based nanoplatforms (carbon nanotubes, fullerenes, nanodiamonds) and quantum dots. This article also gives insight into different biomedical, therapeutic and diagnostic applications of pullulan viz., imaging, tumor targeting, stem cell therapy, gene therapy, vaccine delivery, cosmetic applications, protein delivery, tissue engineering, photodynamic therapy and chaperone-like activities. The review also includes the toxicological profile of pullulan which is helpful for the development of suitable delivery systems for clinical applications.
Collapse
Affiliation(s)
- Ruchira Raychaudhuri
- Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, Karnataka State, India
| | - Santoshi Naik
- Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, Karnataka State, India
| | - Ajjappla B Shreya
- Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, Karnataka State, India
| | - Neha Kandpal
- Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, Karnataka State, India
| | - Abhijeet Pandey
- Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, Karnataka State, India
| | - Guruprasad Kalthur
- Department of Clinical Embryology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal 576104, Karnataka State, India
| | - Srinivas Mutalik
- Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, Karnataka State, India.
| |
Collapse
|
4
|
Meng H, Leong W, Leong KW, Chen C, Zhao Y. Walking the line: The fate of nanomaterials at biological barriers. Biomaterials 2018; 174:41-53. [PMID: 29778981 PMCID: PMC5984195 DOI: 10.1016/j.biomaterials.2018.04.056] [Citation(s) in RCA: 101] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2017] [Revised: 04/15/2018] [Accepted: 04/30/2018] [Indexed: 12/17/2022]
Abstract
Biological systems have developed an efficient multi-tiered defense system to block foreign substances such as engineered nanomaterials (NMs) from causing damage. In a pathological scenario, the disease itself may also pose additional barriers due to the imbalance between abnormal cells and their surrounding microenvironment, and NMs could behave similarly or differently to classic foreign substances, depending on their unique characteristics. Thus, understanding the mechanisms that govern the fate of NMs against these biological barriers, including the strategies that can be used to shift their fate between access and blockage, become key information for NMs design. In this manuscript, we first describe the biological barriers that NMs may encounter, and further discuss how these biological barrier interactions could shift the fate of NMs between toxicity and therapeutic potential. A list of effects that may influence NMs access at nano/bio interface are presented and discussed, followed by personal insights on the important nano/bio topics that require additional research for a better understanding of NM/biological barrier interactions.
Collapse
Affiliation(s)
- Huan Meng
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanosciences and Technology of China, Beijing 100190, China; Department of Medicine, Division of NanoMedicine, University of California, Los Angeles, CA, USA.
| | - Wei Leong
- Department of Biomedical Engineering, Columbia University, New York, NY 10025, USA
| | - Kam W Leong
- Department of Biomedical Engineering, Columbia University, New York, NY 10025, USA
| | - Chunying Chen
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanosciences and Technology of China, Beijing 100190, China; Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Yuliang Zhao
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanosciences and Technology of China, Beijing 100190, China; Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China.
| |
Collapse
|
5
|
Chollet L, Saboural P, Chauvierre C, Villemin JN, Letourneur D, Chaubet F. Fucoidans in Nanomedicine. Mar Drugs 2016; 14:E145. [PMID: 27483292 PMCID: PMC4999906 DOI: 10.3390/md14080145] [Citation(s) in RCA: 67] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Revised: 07/20/2016] [Accepted: 07/21/2016] [Indexed: 12/19/2022] Open
Abstract
Fucoidans are widespread cost-effective sulfated marine polysaccharides which have raised interest in the scientific community over last decades for their wide spectrum of bioactivities. Unsurprisingly, nanomedicine has grasped these compounds to develop innovative therapeutic and diagnostic nanosystems. The applications of fucoidans in nanomedicine as imaging agents, drug carriers or for their intrinsic properties are reviewed here after a short presentation of the main structural data and biological properties of fucoidans. The origin and the physicochemical specifications of fucoidans are summarized in order to discuss the strategy of fucoidan-containing nanosystems in Human health. Currently, there is a need for reproducible, well characterized fucoidan fractions to ensure significant progress.
Collapse
Affiliation(s)
- Lucas Chollet
- Inserm, U1148, LVTS, University Paris Diderot, X Bichat Hospital, F-75877 Paris, France.
- Galilée Institute, University Paris 13, Sorbonne Paris Cité, F-93430 Villetaneuse, France.
- Algues & Mer, Kernigou, F-29242 Ouessant, France.
| | - Pierre Saboural
- Inserm, U1148, LVTS, University Paris Diderot, X Bichat Hospital, F-75877 Paris, France.
- Galilée Institute, University Paris 13, Sorbonne Paris Cité, F-93430 Villetaneuse, France.
| | - Cédric Chauvierre
- Inserm, U1148, LVTS, University Paris Diderot, X Bichat Hospital, F-75877 Paris, France.
- Galilée Institute, University Paris 13, Sorbonne Paris Cité, F-93430 Villetaneuse, France.
| | | | - Didier Letourneur
- Inserm, U1148, LVTS, University Paris Diderot, X Bichat Hospital, F-75877 Paris, France.
- Galilée Institute, University Paris 13, Sorbonne Paris Cité, F-93430 Villetaneuse, France.
| | - Frédéric Chaubet
- Inserm, U1148, LVTS, University Paris Diderot, X Bichat Hospital, F-75877 Paris, France.
- Galilée Institute, University Paris 13, Sorbonne Paris Cité, F-93430 Villetaneuse, France.
| |
Collapse
|